DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information ...

Core Insights - Amarin Corporation, in collaboration with HLS Therapeutics, will present scientific data on Icosapent Ethyl (IPE) at the Canadian Cardiovascular Congress (CCC) from October 23 to 26, 2025, emphasizing their commitment to advancing cardiovascular care [1][2] Group 1: Scientific Presentations - Data presented at CCC 2025 will highlight the clinical value of IPE for cardiometabolic conditions and explore the mechanistic effects of EPA on atherogenic lipoproteins and endothelial cells during inflammation when combined with a GLP-1 receptor agonist [2] - Featured abstracts include a poster presentation on the ENCORE study, which indicates that Icosapent Ethyl reduces cardiovascular disease risk in patients with cardiovascular-kidney-metabolic syndrome [2][3] - An oral presentation will discuss the effects of Icosapent Ethyl on the risk and duration of hospitalizations and death in the REDUCE-IT study [3] Group 2: Product Information - VASCEPA (icosapent ethyl) is the first prescription treatment approved by the FDA solely comprising IPE, launched in the U.S. in January 2020 for high-risk patients with persistent cardiovascular risk despite statin therapy [7] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [7] - VASCEPA is approved and sold in multiple countries, including Canada, China, Australia, and various European nations under the brand name VAZKEPA [7]

Company Overview - Amarin (AMRN) shares increased by 12.5% to close at $18.84, supported by high trading volume, compared to an 11.4% gain over the past four weeks [1] - The price surge is linked to rising investor confidence in Vascepa, Amarin's sole marketed drug, which treats severe hypertriglyceridemia [1] Earnings Expectations - Amarin is projected to report quarterly earnings of $0.31 per share, reflecting a year-over-year increase of 131% [2] - Expected revenues are $42.36 million, showing a slight increase of 0.2% from the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Amarin has remained stable over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [4] Industry Comparison - Amarin operates within the Zacks Medical - Biomedical and Genetics industry, where Fortrea Holdings Inc. (FTRE) has seen a decline of 1.6% to $9.45, with a monthly return of -8.7% [4] - Fortrea's consensus EPS estimate has decreased by 13.3% over the past month to $0.15, representing a 34.8% decline from the previous year [5]

Core Insights - The article emphasizes the importance of strong brand recognition, solid financials, and growth potential in identifying profitable investment opportunities within the consumer products sector [1] Group 1: Investment Focus - The company specializes in the consumer products sector, focusing on identifying firms that combine strong brand recognition with solid financial performance [1] - There is a keen observation of consumer trends, which aids in recognizing potential investment opportunities [1] Group 2: Analytical Approach - The analysis is based on an in-depth understanding of the industry, which enhances the ability to identify profitable investments [1]

Core Insights - Amarin Corporation presented in vitro data on the effects of eicosapentaenoic acid (EPA) on lipoprotein(a) [Lp(a)] oxidation and its potential anti-inflammatory mechanisms at the European Society of Cardiology Congress 2025 [1][2] Mechanisms of Action - The in vitro analyses suggest that EPA may reduce inflammation in atherosclerotic cardiovascular disease (ASCVD) and impact cardiovascular events in at-risk patients with elevated Lp(a) [2][6] - EPA modulates inflammasome activation in monocyte-derived macrophages (MDMs), which may be linked to cardiovascular risk reduction beyond triglyceride lowering [3][5] - Key findings indicate that EPA may reduce extracellular ATP release and caspase 1 activation in stimulated MDMs, providing preliminary evidence of its protective role against inflammation in ASCVD [5][6] Effects on Lipoprotein(a) - Elevated Lp(a) is associated with increased ASCVD risk, and EPA has been shown to inhibit Lp(a) oxidation and its effects on oxidative stress and pro-inflammatory protein expression in endothelial cells [7][8] - The analysis indicates that EPA's lipid-centric scavenging mechanism may inhibit lipoprotein oxidation, thereby reducing its impact on endothelial dysfunction and inflammation [9] Company Overview - Amarin is focused on advancing cardiovascular disease management and increasing scientific understanding of persistent cardiovascular risk beyond traditional therapies [10][11] - VASCEPA (icosapent ethyl) is the first FDA-approved prescription treatment solely comprising this active ingredient, launched in the U.S. in January 2020 for high-risk patients [12][13]

Core Insights - The 2025 ESC/EAS Dyslipidemia Guideline Update reaffirms high-dose icosapent ethyl (IPE) as a Class IIA recommended therapy for high-risk or very high-risk patients to reduce cardiovascular events based on the REDUCE-IT trial findings [1][14] Group 1: REDUCE-IT Trial Findings - Three sub-analyses from the REDUCE-IT trial demonstrate significant reductions in cardiovascular disease (CVD) risk and outcomes associated with IPE administration in patients with cardiovascular-kidney-metabolic (CKM) syndrome, stratified by baseline apolipoprotein B (ApoB) and fasting triglyceride-rich lipoprotein cholesterol (TRL-C) levels [1][2] - IPE treatment showed a 44% relative risk reduction (RRR) for the primary composite endpoint in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², with a hazard ratio (HR) of 0.56 (95% CI 0.39, 0.79), P = 0.001, and an absolute risk reduction (ARR) of 11.2% [4][5] Group 2: Impact on Major Adverse Cardiovascular Events (MACE) - IPE treatment resulted in significant reductions in MACE across all quartiles of baseline ApoB and TRL-C concentrations, with HRs ranging from 0.72 to 0.80 for ApoB and from 0.74 to 0.68 for TRL-C, all with P ≤ 0.02 [8][9] Group 3: Hospitalization and Mortality Outcomes - IPE significantly reduced total hospitalizations (HR 0.91, 95% CI 0.84, 0.98, P=0.017) and increased the likelihood of surviving without hospitalization (odds ratio (OR) 1.12, 95% CI 1.02, 1.22, P=0.016) [12][13] Group 4: Clinical Recommendations - The ESC/EAS guidelines recommend high-dose IPE for patients with elevated triglyceride levels (135–499 mg/dL) despite statin therapy, emphasizing its role in reducing CVD events [14]

Core Insights - Amarin Corporation will present new data on icosapent ethyl (IPE) at the European Society of Cardiology (ESC) Congress 2025, highlighting its cardioprotective effects [1][2] - The data will focus on IPE's role in reducing cardiovascular risk through various mechanisms, including inflammation and lipoprotein oxidation [2][3] Presentation Highlights - New analyses from the REDUCE-IT trial will evaluate the clinical benefits of IPE, including its impact on hospitalization risk and duration [2][3] - Mechanistic studies will explore the effects of eicosapentaenoic acid (EPA) on inflammasome activation and pro-inflammatory protein expression in endothelial cells [2][3] Educational Initiatives - Amarin will support educational programming addressing residual cardiovascular risk, featuring presentations by medical and scientific leaders in Europe [3][5] Symposium and Abstracts - Moderated poster presentations will include topics such as the reduction of cardiovascular disease risk in cardiovascular-kidney-metabolic syndrome and the impact of IPE across different apolipoprotein B and triglyceride levels [4][7] - Oral presentations will cover the effects of IPE on hospitalization risks and the modulation of inflammasome activation in macrophages [7] Company Overview - Amarin is focused on advancing cardiovascular disease management and understanding residual cardiovascular risk beyond traditional therapies [8] - The company has a global presence with offices in the United States, Ireland, Switzerland, and partnerships worldwide [8] Product Information - VASCEPA (icosapent ethyl) is the first FDA-approved treatment solely comprising IPE, aimed at high-risk patients with persistent cardiovascular risk despite statin therapy [9] - Since its launch, VASCEPA has been prescribed over 25 million times and is covered by most major medical insurance plans [9]

Core Viewpoint - Amarin (AMRN) shares have recently declined by 5.4% over the past four weeks, but the formation of a hammer chart pattern suggests potential support and a possible trend reversal in the future [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottoming out, with reduced selling pressure, which could lead to a bullish trend for the stock [2][5]. - A hammer pattern forms when there is a small candle body with a long lower wick, signaling that buyers are starting to emerge after a downtrend [4][5]. - The effectiveness of the hammer pattern is enhanced when used alongside other bullish indicators, as its strength is dependent on its placement on the chart [6]. Fundamental Analysis - There has been a recent upward trend in earnings estimate revisions for Amarin, which is a positive sign for the stock's future performance [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 2%, indicating that analysts expect better earnings than previously predicted [8]. - Amarin currently holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9][10].

Company Performance - Amarin (AMRN) has returned approximately 56% since the beginning of the calendar year, significantly outperforming the average loss of 6.1% in the Medical sector [4] - The Zacks Consensus Estimate for AMRN's full-year earnings has increased by 50.1% over the past quarter, indicating improved analyst sentiment and a more positive earnings outlook [3] Sector and Industry Comparison - Amarin is part of the Medical sector, which includes 979 individual stocks and currently holds a Zacks Sector Rank of 7 [2] - Within the Medical - Biomedical and Genetics industry, which consists of 489 companies, Amarin ranks 144 in the Zacks Industry Rank, outperforming the average gain of 0.2% in this group [5] - Bayer Aktiengesellschaft (BAYRY), another stock in the Medical sector, has a year-to-date return of 63.1% and also holds a Zacks Rank of 2 (Buy) [4][5] Investment Outlook - Investors interested in Medical stocks should continue to monitor Amarin and Bayer Aktiengesellschaft, as both stocks are expected to maintain their strong performance [6]

Core Insights - Amarin Corporation (AMRN) reported a narrower loss of $0.03 per share for Q2 2025, compared to the Zacks Consensus Estimate of a loss of $0.66 per share, and break-even earnings in the same quarter last year [1][7] - Total revenues for Q2 2025 were $72.7 million, exceeding the Zacks Consensus Estimate of $46 million, and representing an 8% increase from the previous year, driven by higher licensing and royalty revenues [2][7] Financial Performance - Adjusted earnings, excluding stock-based compensation, licensing fees, and restructuring expenses, were $0.04 per share, up from $0.01 per share in the year-ago quarter [2] - Net product revenues from Vascepa, the company's sole marketed drug, were $46.6 million, a 2% decline year-over-year, with U.S. product revenues down 17% to $36.5 million due to increased generic competition [4][8] - Licensing and royalty revenues increased by 31% year-over-year to $26.1 million, attributed to an upfront payment from a European licensing agreement and higher royalties [8] Market Reaction - Shares of Amarin rose by 2.2% on July 30 following the better-than-expected results, with the stock up 54.3% year-to-date compared to a 1% rise in the industry [3] Strategic Developments - In June 2025, Amarin signed a long-term exclusive licensing agreement with Recordati to commercialize Vazkepa in 59 European countries, receiving an upfront payment of $25 million and potential milestone payments of up to $150 million [10][11] - A global restructuring initiative is expected to save approximately $70 million over the next 12 months, which is anticipated to enhance European growth [7][11] Cash Position - As of the end of Q2 2025, Amarin had cash and investments totaling $298.7 million, an increase from $281.8 million as of March 31, 2025 [9]